Heron Therapeutics, Inc. (0J4V.L)
USD 1.62
(0.31%)
USD 1.62
(0.31%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 173.75 Million USD | 14.07% |
| 2022 | 157.47 Million USD | -1.27% |
| 2021 | 159.49 Million USD | 548.06% |
| 2020 | 24.61 Million USD | 24.35% |
| 2019 | 19.79 Million USD | 332.71% |
| 2018 | 4.57 Million USD | -84.05% |
| 2017 | 28.68 Million USD | -45.79% |
| 2016 | 52.91 Million USD | 2281.23% |
| 2015 | 2.22 Million USD | 39.05% |
| 2014 | 1.59 Million USD | 55.9% |
| 2013 | 1.02 Million USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 179.17 Million USD | -0.25% |
| 2024 Q2 | 174.22 Million USD | -0.26% |
| 2023 Q2 | 156.12 Million USD | -0.51% |
| 2023 Q1 | 156.92 Million USD | -0.35% |
| 2023 Q3 | 179.99 Million USD | 15.29% |
| 2023 Q4 | 179.62 Million USD | -0.21% |
| 2023 FY | 179.62 Million USD | 14.07% |
| 2022 Q2 | 158.51 Million USD | -0.31% |
| 2022 Q1 | 159 Million USD | -0.31% |
| 2022 FY | 157.47 Million USD | -1.27% |
| 2022 Q4 | 157.47 Million USD | -0.33% |
| 2022 Q3 | 158 Million USD | -0.32% |
| 2021 Q4 | 159.49 Million USD | -3.04% |
| 2021 Q3 | 164.5 Million USD | -0.4% |
| 2021 FY | 159.49 Million USD | 548.06% |
| 2021 Q1 | 24.42 Million USD | 13.01% |
| 2021 Q2 | 165.15 Million USD | 576.15% |
| 2020 Q1 | 22.64 Million USD | 26.73% |
| 2020 FY | 24.61 Million USD | 24.35% |
| 2020 Q2 | 22.28 Million USD | -1.59% |
| 2020 Q3 | 21.93 Million USD | -1.55% |
| 2020 Q4 | 21.61 Million USD | -1.46% |
| 2019 Q4 | 17.86 Million USD | 10.71% |
| 2019 Q3 | 16.13 Million USD | -1.19% |
| 2019 Q2 | 16.33 Million USD | -1.28% |
| 2019 Q1 | 16.54 Million USD | 261.7% |
| 2019 FY | 19.79 Million USD | 332.71% |
| 2018 FY | 4.57 Million USD | -84.05% |
| 2018 Q4 | 4.57 Million USD | 5.44% |
| 2018 Q3 | 4.33 Million USD | -85.1% |
| 2018 Q2 | 29.11 Million USD | 0.75% |
| 2018 Q1 | 28.89 Million USD | 0.73% |
| 2017 Q3 | 28.48 Million USD | 0.69% |
| 2017 FY | 28.68 Million USD | -45.79% |
| 2017 Q2 | 28.28 Million USD | -46.73% |
| 2017 Q1 | 53.09 Million USD | 0.35% |
| 2017 Q4 | 28.68 Million USD | 0.71% |
| 2016 Q3 | 52.73 Million USD | 1961.45% |
| 2016 Q2 | 2.55 Million USD | 7.12% |
| 2016 Q4 | 52.91 Million USD | 0.34% |
| 2016 FY | 52.91 Million USD | 2281.23% |
| 2016 Q1 | 2.38 Million USD | 7.47% |
| 2015 FY | 2.22 Million USD | 39.05% |
| 2015 Q1 | 1.74 Million USD | 9.45% |
| 2015 Q4 | 2.22 Million USD | 7.81% |
| 2015 Q3 | 2.06 Million USD | 8.3% |
| 2015 Q2 | 1.9 Million USD | 8.81% |
| 2014 FY | 1.59 Million USD | 55.9% |
| 2014 Q2 | 1.3 Million USD | 12.2% |
| 2014 Q3 | 1.45 Million USD | 11.03% |
| 2014 Q4 | 1.59 Million USD | 10.21% |
| 2014 Q1 | 1.16 Million USD | 13.56% |
| 2013 Q3 | 888 Thousand USD | 17.77% |
| 2013 Q2 | 754 Thousand USD | 21.22% |
| 2013 Q4 | 1.02 Million USD | 15.43% |
| 2013 Q1 | 622 Thousand USD | 0.0% |
| 2013 FY | 1.02 Million USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -375.567% |
| Dynavax Technologies Corporation | 256.91 Million USD | 32.369% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -318.41% |
| Perrigo Company plc | 4.07 Billion USD | 95.734% |
| Illumina, Inc. | 2.26 Billion USD | 92.319% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.502% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -17275.3% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 98.181% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 98.779% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 93.572% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -543.768% |
| Waters Corporation | 2.35 Billion USD | 92.624% |
| Biogen Inc. | 7.33 Billion USD | 97.632% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -355.997% |
| Evolus, Inc. | 126.54 Million USD | -37.304% |
| Adicet Bio, Inc. | 17.7 Million USD | -881.489% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -302.513% |
| bluebird bio, Inc. | 330.32 Million USD | 47.4% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 67.88% |
| FibroGen, Inc. | 170.45 Million USD | -1.935% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 93.647% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -731.982% |
| Homology Medicines, Inc. | 44.05 Million USD | -294.409% |
| Geron Corporation | 85.89 Million USD | -102.276% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 92.754% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 60.96% |
| Myriad Genetics, Inc. | 145 Million USD | -19.83% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -13689.921% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -50.636% |
| Zoetis Inc. | 6.8 Billion USD | 97.446% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -3847.138% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 91.985% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 84.676% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 78.507% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -378.355% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 88.046% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -200.237% |
| Verastem, Inc. | 41.55 Million USD | -318.108% |
| Nektar Therapeutics | 230.4 Million USD | 24.587% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 6.771% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -5552.342% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 87.561% |
| OPKO Health, Inc. | 326.56 Million USD | 46.794% |
| Exelixis, Inc. | 189.94 Million USD | 8.524% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 59.441% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -114968.212% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | -25.536% |
| Imunon, Inc. | 1.13 Million USD | -15150.949% |
| Blueprint Medicines Corporation | 774.12 Million USD | 77.555% |
| Insmed Incorporated | 1.2 Billion USD | 85.569% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 88.411% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -204.894% |
| TG Therapeutics, Inc. | 110.79 Million USD | -56.824% |
| Incyte Corporation | 38.28 Million USD | -353.817% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 80.199% |